DIATHERIX Laboratories Presents at Homeland Security Conference
|
| Posted
:
Wed, 04 Nov 2009 18:57:27 GMT |
| Author
:
DIATHERIX Laboratories, Inc. |
| Category
:
Press Release |
| News Alerts by
Email ( click
here ) |
|
|
|
|
HUNTSVILLE, Ala., Nov. 4 AL-DIATHERIX-at-MiSN
HUNTSVILLE, Ala., Nov. 4 /PRNewswire/ -- DIATHERIX Laboratories, Inc. (DIATHERIX) (www.DIATHERIX.com), today presented at the Michigan Security Network Homeland Security Market Leadership Conference in Dearborn, Mich. Dennis Grimaud, Chairman and Chief Executive Officer of DIATHERIX, explained the impact of the company's advanced molecular diagnostic testing on bio-preparedness, pandemic response, infectious disease diagnosis and military efforts.
"This conference is especially timely because last week Congress reported the government is failing to properly address the urgent and immediate threat of biological terrorism. If our country were faced with a biological attack, fast and accurate testing would be critical in properly containing the outbreak and properly treating victims," said Grimaud. "In addition, in light of the current H1N1 pandemic, it was an opportune time to discuss how early, simultaneous detection of the H1N1 strain and bacterial co-infections can help effectively identify and treat those patients at highest risk and control the spread of the virus."
DIATHERIX uses Target Enriched Multiplex Polymerase Chain Reaction (Tem-PCR), the company's proprietary molecular technology, to test for multiple pathogens, both viral and bacterial in a single test. Patient results are available the next day, providing physicians with quick and accurate information from which to develop an effective course of treatment.
During the conference, where more than 20 presenters discussed biotechnology and biodefense, Grimaud also addressed Tem-PCR's military application. "Our technology can also detect infectious agents from multiple environmental sample types," said Grimaud. If we detect these agents in regions where our military serves, we can take preventive measures to protect them."
The Michigan Security Network (MiSN) is a non-profit organization that serves as a platform to accelerate technology development, investment and jobs in the state of Michigan in the fast-growing homeland security sector. This is the organization's first technology conference. "Our market analysis on existing technology gaps in homeland security and our work with technology companies have given the MiSN an insider's understanding of the innovations available in the marketplace, like Diatherix," said MiSN Chief Executive Officer and Founder Leslie Touma. "Our goal is to serve as a market connector, serving a critical role in bringing together technology creators with the businesses and first responders that will use their leading edge advancements to save lives -- whether it's swine flu, new pandemics or biodefense on the battlefield."
DIATHERIX Laboratories, Inc. is located in the HudsonAlpha Institute for Biotechnology in Huntsville, Ala. DIATHERIX operates as an independent high complexity CLIA-certified clinical laboratory providing advanced multiplex molecular diagnostic services to assist healthcare providers in the detection of infectious disease. For more information, please visit the company's web site at www.DIATHERIX.com.
Available Topic Expert(s): For information on the listed expert, click appropriate link.
Dennis Grimaud
https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=86216
SOURCE DIATHERIX Laboratories, Inc.
|
Copyright © 2008
PR Newswire. All rights reserved.
|
|
|
|
|
Related
News
Research and Markets: Frost & Sullivan's Middle East Business Jets Market Assessment Report: Middle East Business Jets Market is on an Upswing Despite the Economic Downturn DUBLIN -
Research and Markets (
Research and Markets: Substance Abuse Treatment for Youth and Adults: State-of-the-Art Clinician's Guide to Evidence-Based Practice DUBLIN -
Research and Markets (
Research and Markets: Microelectromechanical Systems Foundries 2009 Report DUBLIN -
Research and Markets (
Oxagen Limited Raises £16 Million in Series C Private Venture Capital Financing Led by Novartis Venture Funds ABINGDON, UK -
Oxagen Limited, a drug discovery and development company specializing in
inflammation, announced today the successful completion of a £16 Million
($26.7 Million) Series C round led by Novartis Venture Funds.
The proceeds of the funding will be used primar
Global Concentrated Photovoltaic Market Worth US$266.0 million by 2014
WILMINGTON, Delaware, November 24 /PRNewswire/ -- According to the new
market research report, 'Concentrated Photovoltaic and Solar Photovoltaic
Global Markets (2009 - 2014)', published by MarketsandMarkets
(www....
Bannerman Results of 2009 Annual General Meeting PERTH, AUSTRALIA -- 11/24/09 --
Bannerman Resources Limited (ASX: BMN)(TSX: BAN)(NSX: BMN) ("Bannerman" or the "Company") is pleased to advise that all resolutions put to shareholders at the Annual General Meeting were duly carried on a show of han..
Shazam Launches (SHAZAM)RED on App Store LONDON -
Shazam, the world’s leading mobile music discovery provider, today
announced the availability of its (PRODUCT)REDTM Special
Edition App on the App Store. New iPhone and iPod touch users who
download the (SHAZAM)RED App, or existing users who upgrade,
|
|
|
|
|
|
|
|
|